Pediatric Radiology

, Volume 44, Issue 7, pp 857–862 | Cite as

OK-432 sclerotherapy of lymphatic malformation in the head and neck: factors related to outcome

Original Article

Abstract

Background

No previous study to the best of our knowledge has examined the multiple factors related to the outcome of OK-432 sclerotherapy of lymphatic malformations.

Objective

This study aimed to assess factors related to the successful outcome of OK-432 sclerotherapy for lymphatic malformations in the head and neck region.

Materials and methods

During a 6-year period, OK-432 sclerotherapy was performed in 26 patients with lymphatic malformations. Several factors related to the efficacy of OK-432 sclerotherapy were evaluated, including the type (macrocystic or microcystic), the maximum lesion diameter, amount and hemorrhagic cytology of the aspirate, degree of aspiration, injected dose of OK-432 and post-therapy inflammation-related symptom. In all cases, ultrasound (US) follow-up was performed.

Results

Of the 26 cases, 13 (50%) showed successful elimination of the lymphatic malformations in the follow-up US after the initial session, and all successful cases were of the macrocystic type. The type of lymphatic malformation and the success of OK-432 sclerotherapy were significantly related (P = 0.0149). Of the 16 cases of complete aspiration, 11 (68.8%) showed a successful outcome. Further, of the 17 cases with inflammation-related symptom, 13 (76.5%) showed a successful outcome. While the degree of aspiration and presence of inflammation-related symptom showed a significant relationship with the success of OK-432 sclerotherapy (P < 0.05), no other factors showed a significant relationship.

Conclusion

The study results suggest that the macrocystic type and complete aspiration of cystic contents were important factors for the success of OK-432 sclerotherapy of lymphatic malformations, and that inflammation-related symptom was a predictor of a successful outcome.

Keywords

Head and neck Lymphatic malformation OK-432 Sclerotherapy Ultrasound Child Adult 

Notes

Conflict of interest

None.

References

  1. 1.
    Hamoir M, Plouin-Gaudon I, Rombaux P et al (2001) Lymphatic malformations of the head and neck: a retrospective review and a support for staging. Head Neck 4:326–337Google Scholar
  2. 2.
    Giguere CM, Bauman NM, Sato Y et al (2002) Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial. Arch Otolaryngol Head Neck Surg 10:1137–1144CrossRefGoogle Scholar
  3. 3.
    Banieghbal B, Davies MR (2003) Guidelines of the successful treatment of lymphangioma with OK-432. Eur J Pediatr Surg 2:103–107Google Scholar
  4. 4.
    Narkio-Makela M, Makel T, Saarinen P et al (2011) Treatment of lymphatic malformations of head and neck with OK-432 sclerotherapy induce systemic inflammatory response. Eur Ach Otorhinolaryngol 268:123–129CrossRefGoogle Scholar
  5. 5.
    Ogita S, Tsuto T, Tokiwa K et al (1987) Treatment of cystic hygroma in children with special reference to OK-432 therapy. Z kinderchir 5:279–281Google Scholar
  6. 6.
    Orvidas LJ, Kasperbauer JL (2000) Pediatric lymphangiomas of the head and neck. Ann Otol Rhinol Laryngol 4:411–421Google Scholar
  7. 7.
    Burrows PE, Mitri RK, Alomari A et al (2008) Percutaneous sclerotherapy of lymphatic malformations with doxycycline. Lymphat Res Biol 3:209–216CrossRefGoogle Scholar
  8. 8.
    Hall N, Ade-Ajayi N, Brewis C et al (2003) Is intralesional injection of OK-432 effective in the treatment of lymphangioma in children? Surgery 3:238–242CrossRefGoogle Scholar
  9. 9.
    Rautio R, Keski-Nisula L, Laranne J et al (2003) Treatment of lymphangiomas with OK-432 (Picibanil). Cardiovasc Intervent Radiol 1:31–36Google Scholar
  10. 10.
    Smith MC, Zimmerman MB, Burke DK et al (2009) OK-432 Collaborative Study Group. Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope 1:107–115CrossRefGoogle Scholar
  11. 11.
    Niramis R, Watanatittan S, Rattanasuwan T (2010) Treatment of cystic hygroma by intralesional bleomycin injection: experience in 70 patients. Eur J Pediatr Surg 20:178–182PubMedCrossRefGoogle Scholar
  12. 12.
    Shiels WE 2nd, Kang DR, Murakami JW et al (2009) Percutaneous treatment of lymphatic malformations. Otolaryngol Head Neck Surg 141:219–224PubMedCrossRefGoogle Scholar
  13. 13.
    Puig S, Aref H, Brunelle F (2003) Double-needle sclerotherapy of lymphangiomas and venous angiomas in children: a simple technique to prevent complications. AJR Am J Roentgenol 180:1399–1401PubMedCrossRefGoogle Scholar
  14. 14.
    Schmidt B, Schimpl G, Hollwarth ME (1996) OK-432 therapy of lymphangiomas in children. Eur J Pediatr 155:649–652PubMedCrossRefGoogle Scholar
  15. 15.
    Brewis C, Pracy JP, Albert DM (2000) Treatment of lymphangiomas of the head and neck in children by intralesional injection of OK-432 (Picibanil). Clin Otolaryngol Allied Sci 25:130–134PubMedCrossRefGoogle Scholar
  16. 16.
    Luzzatto C, Midrio P, Tchaprassian Z et al (2000) Sclerosing treatment of lymphangiomas with OK-432. Arch Dis Child 82:316–318PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Sichel JY, Udassin R, Gozal D et al (2004) OK-432 therapy for cervical lymphangioma. Laryngoscope 114:1805–1809PubMedCrossRefGoogle Scholar
  18. 18.
    Okazaki T, Iwatani S, Yanai T et al (2007) Treatment of lymphangioma in children: our experience of 128 cases. J Pediatr Surg 42:386–389PubMedCrossRefGoogle Scholar
  19. 19.
    Yoo JC, Ahn Y, Lim YS et al (2009) OK-432 sclerotherapy in head and neck lymphangiomas: long-term follow-up result. Otolaryngol Head Neck Surg 140:120–123PubMedCrossRefGoogle Scholar
  20. 20.
    Ogita S, Tsuto T, Nakamura K et al (1996) OK-432 therapy for lymphangioma in children: why and how does it work? J Pediatr Surg 31:477–480PubMedCrossRefGoogle Scholar
  21. 21.
    Yang KD, Stone RM, Lee CS et al (1992) Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: implication of monocyte-derived neutrophil-activating factors. Cancer Immunol Immunother 35:277–282PubMedCrossRefGoogle Scholar
  22. 22.
    Rho MH, Kim DW, Kwon JS et al (2006) OK-432 sclerotherapy of plunging ranula in 21 patients: it can be a substitute for surgery. AJNR Am J Neuroradiol 27:1090–1095PubMedGoogle Scholar
  23. 23.
    Reismann M, Chaffarpour N, Luvall E et al (2013) Dynamic Toll-like receptor expression predicts outcome of sclerotherapy for lymphatic malformations with OK-432 in children. J Surg Res. doi:10.1016/j.jss.2013.09.037 PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of RadiologyBusan Paik Hospital, Inje University College of MedicineBusanRepublic of Korea

Personalised recommendations